Holen Sie sich die Stockscreener-App
23.13
10.04%
2.11
Handel nachbörslich:
23.13
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Evommune (NYSE:EVMN) Trading Up 10.2%Still a Buy? - MarketBeat
Evommune (NYSE:EVMN) Stock Price Down 7.6%Should You Sell? - MarketBeat
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
Evommune, Inc.(NYSE: EVMN) added to S&P Global BMI Index - marketscreener.com
EVMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit - Kalkine Media
Evommune (NYSE:EVMN) Upgraded at Clear Str - MarketBeat
Evommune stock sees RS rating rise to 91 - MSN
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Technical Analysis of Evommune, Inc. (NYSE:EVMN) - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Analysts Set Expectations for Evommune FY2027 Earnings - MarketBeat
Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise - TipRanks
H.C. Wainwright cuts Evommune stock price target on dilution - Investing.com UK
H.C. Wainwright cuts Evommune stock price target on dilution By Investing.com - Investing.com India
HC Wainwright Cuts Evommune (NYSE:EVMN) Price Target to $50.00 - MarketBeat
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
EVMN Stock: HC Wainwright & Co. Lowers Price Target to $50 | EVM - GuruFocus
Clear Street initiates Evommune stock with buy rating on drug potential - Investing.com India
Clear Street initiates Evommune stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Evommune (NYSE:EVMN) Stock Price Up 7.5%Should You Buy? - MarketBeat
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - The Chronicle-Journal
Leerink reiterates Evommune stock rating after conference chat By Investing.com - Investing.com India
Leerink reiterates Evommune stock rating after conference chat - Investing.com Nigeria
RBC Capital initiates Evommune stock with outperform rating By Investing.com - Investing.com Canada
RBC Capital initiates Evommune stock with outperform rating - Investing.com
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade - AOL.com
Evommune initiated with an Outperform at RBC Capital - TipRanks
Evommune (NYSE:EVMN) Trading Down 6.7%Here's What Happened - MarketBeat
Evommune (EVMN) Earnings Loss Deepens Narrative Around Heavy Spending And Unprofitability - Sahm
Evommune (NYSE:EVMN) Trading 6.9% HigherTime to Buy? - MarketBeat
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlight - PharmiWeb.com
Evommune Reports Q4 2025 Results and Pipeline Progress - TipRanks
Evommune reports Q4 EPS ($1.43), consensus (84c) - TipRanks
Evommune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Joplin Globe
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune, Inc. announced that it has received $125.300499 million in funding - marketscreener.com
Evommune, Inc.: Lead in MRGPRX2 Modulation and Differentiated EVO756 Profile Support Buy Rating - TipRanks
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):